Conference Coverage
Conference Coverage
PD-L1 cutoff for pembrolizumab in mTNBC confirmed
PD-L1 CPS of at least 10 improves overall survival by 28%-29%. Further analysis of responses to pembrolizumab plus chemotherapy in metastatic TNBC...
Latest News
Pembrolizumab improves event-free survival in early TNBC
Neoadjuvant pembrolizumab benefits early TNBC patients regardless of disease stage and nodal status. Event-free survival improved by about 35%...
Conference Coverage
ASH studies look at racial disparities in ALL care, outcomes
Findings of two studies on U.S. blood cancer care suggest that “structural racism” may play a role in worse outcomes among young Hispanic and...
Conference Coverage
NHL: As a second-line treatment in phase 3 trial, tisa-cel disappoints
In this phase 3 BELINDA study, CAR T-cell therapy did not prolong event-free survival as a second-line treatment of aggressive non-Hodgkin...
Conference Coverage
TKI/BiTE combo extends survival of older patients with Ph+ALL
In these elderly patients who are not candidates for chemo, the issue is whether we can prolong remission by the addition of other treatments,...
Conference Coverage
AGILE: ‘Exciting’ survival results for IDH1-mutated AML
Results show survival that is three times longer for a combination of ivosidenib plus azacitidine versus azacitidine alone in a distinct...
Conference Coverage
Isatuximab added to RVd boosts response in new myeloma
A drug approved in 2020 for treatment of advanced multiple myeloma has been shown to benefit patients newly diagnosed with the disease.
Conference Coverage
Antibiotic use associated with triple-negative breast cancer mortality
Antimicrobials can decrease circulating and tumor-infiltrating lymphocytes that effect the immune repertoire and in turn survival.
Conference Coverage
Omega-3 supplements may impact breast cancer risk
Two small studies suggest gut microbiota changes could influence susceptibility.
Conference Coverage
Women struggle with benzodiazepine addiction post chemotherapy treatment
Sedatives like benzodiazepines are used to control nausea, anxiety, and insomnia during chemotherapy treatment, but overuse and failing to taper...
Conference Coverage
‘Surprising’ lack of benefit to adding palbociclib to endocrine therapy in early HR+/HER2– breast cancer
Two years of adjuvant palbociclib with endocrine therapy failed to improve invasive disease-free survival in patients with stage II-III HR-...